Boundless Bio

For the first time as a public company, we're excited to announce our financial results for the first quarter of 2024 and highlight recent progress, including initiation of targeted therapy combinations in our ongoing Phase 1/2 POTENTIATE clinical trial of BBI-355, the first patient dosed in the Phase 1/2 STARMAP study of BBI-825 in patients with resistance gene amplifications, and the completion of our recent IPO. Read more: https://lnkd.in/gskw__rK

Last year, our summer #FoodDrive event brought the life science industry together to provide 7,738 meals to food-insecure students throughout San Diego! As we kick off this year’s food drive, we look forward to giving back to our community again as we strive to provide 10,000 meals to students in need. 🥑 🥕 🥖 On Friday, June 14, we’ll partner with Feeding San Diego for our annual community-wide Food Drive event aimed at addressing the summer meal gap that exists when local students do not have access to meals provided in school. 📣 Life Science companies in San Diego are invited to join our food drive! Please like and share this post to amplify! 📣 Be sure to register for the event before the May 24 deadline: https://lnkd.in/gn-xgJWp Thank you to our partners who have already signed up! Alexandria Real Estate Equities, Inc. aTyr Pharma  Boundless Bio Cellics Therapeutics, Inc. Biocom California Erasca, Inc. Neurelis, Inc. Illumina #FeedingBodiesFuelingMinds

Next week, Boundless Chief Financial Officer, Jami Rubin, will take the stage to present at the Citizens JMP Life Sciences Conference 2024 and provide a corporate update. Join us via webcast Monday, May 13 at 1:00 p.m. ET to catch the presentation: https://lnkd.in/ePYWJnDf Read more: https://lnkd.in/e2du-f2P

Please join us in expressing our heartfelt gratitude to a vital member of our team, Myra Balatan!   Myra, our exceptional Executive Assistant and Office Manager, embodies dedication and passion in everything she does. Her unwavering support keeps our operations running seamlessly. She's here to make a difference for Boundless and our mission to bring new therapeutics to patients with cancer. Her unwavering commitment drives us closer to our shared goals.   Thank you, Myra, and happy #AdministrativeProfessionalsDay!

As #LaboratoryProfessionalsWeek comes to an end, we want to give one final shoutout to our amazing lab-focused BoundTowners. We spent the week celebrating with treats, games, prizes, and delicious food, all to honor our stellar lab professionals. We have endless gratitude for each and every one of you for your invaluable contributions to our team, the strides you make every day, and the efforts you put forth to push new frontiers in oncology. Thank you for everything you do!

“This is an important step along our journey…the IPO isn’t an outcome in and of itself, but it’s a mechanism to bring in capital to continue to support the important scientific research that we’re performing,” said Boundless Chief Executive Officer, Zachary Hornby. Check out the conversation with Nasdaq in their “Behind the Bell” feature on our recent IPO listing and the work we’re doing to bring new hope to cancer patients. 

Today we announced that the first patient has been dosed with BBI-825, our second ecDNA-directed therapy (ecDTx), in a first-in-human, Phase 1/2 clinical trial for cancer patients with resistance gene amplifications. BBI-825 is a novel, oral, selective small molecule inhibitor of RNR, a rate-limiting enzyme responsible for the de novo synthesis of dNTPs, the building blocks of DNA, and essential to the assembly and repair of ecDNA. “We are excited to announce dosing of the first patient in our first-in-human study of BBI-825, our second program to enter the clinic,” said Klaus Wagner, M.D., Ph.D., Chief Medical Officer at Boundless Bio. “BBI-825 represents a new approach in the potential treatment of oncogene amplifications, particularly in resistance associated with targeted therapy treatment of MAPK pathway-activated cancers.”   Read more from our release below. https://lnkd.in/eXZCQ64W

As #AACR24 is underway, we’re pleased to present preclinical and clinical pharmacodynamic data supporting the ongoing clinical development of our lead #ecDNA directed therapy, BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1). BBI-355 demonstrated substantial antitumor activity, including complete and durable regressions, across multiple oncogene amplified preclinical tumor models. We also present additional research on ecDNA-mediated acquired resistance to #chemotherapy. Read the full details: https://lnkd.in/eGPnxJGC

Today’s bell ringing ceremony was extra special for Boundless Bio, celebrating alongside inspiring students from DREAM New York Charter High School. Thank you Life Science Cares San Diego and Life Science Cares New York for bringing us together. These stellar students helped us ring in our big day all while learning first-hand about the #IPO process and stock market. Thank you for joining us!

A $BOLD step forward for Boundless and patients with oncogene amplified cancer. Today, we celebrate our #IPO at Nasdaq during the opening bell ringing ceremony.    We are energized and committed to our pursuit of novel, potentially life-improving treatment options for patients with oncogene amplified cancers. Thank you to our team, partners, investors and supporters – here’s to our next chapter!